Hemab raises USD 157 million in Series C financing

Hemab announces a USD 157 million multifold oversubscribed Series C financing led by Sofinnova Partners, with participation from both new and existing investors, including RA Capital Management, Novo Holdings, Access Biotechnology, Deep Track Capital, HealthCap, Invus, Avoro Ventures, Maj Invest Equity, and Rock Springs Capital.

Founded in 2020, Hemab is a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders like Glanzmann Thrombasthenia, FVII Deficiency, and Von Willebrand Disease. The Series C financing will support Hemab for registration studies following successful advancement of sutacimig through Phase 2 in Glanzmann thrombasthenia, continued progress of HMB-002 in Von Willebrand disease, and to advance additional novel drug candidates into clinical development.

Mazanti Transactions has advised Hemab in connection with all aspects of the investment round.